Alexandra Trkola

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
    Alexandra Trkola
    Division of Infectious Diseases, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:395-400. 2002
  2. ncbi Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
  3. ncbi In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
  4. ncbi HIV-host interactions: vital to the virus and key to its inhibition
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Opin Microbiol 7:555-9. 2004
  5. ncbi HIV-host interactions: vital to the virus and key to its inhibition
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Opin Microbiol 7:407-11. 2004
  6. ncbi Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008
  7. ncbi Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Blood 104:1784-92. 2004
  8. ncbi Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Virol 77:13146-55. 2003
  9. ncbi Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    Michael Huber
    Division of Infectious Diseases, , , Switzerland
    PLoS Med 3:e441. 2006
  10. ncbi Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010

Detail Information

Publications33

  1. ncbi HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
    Alexandra Trkola
    Division of Infectious Diseases, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:395-400. 2002
    ..Instead, HIV-1 acquires the ability to use CCR5 despite the inhibitor, first by requiring lower levels of CCR5 for entry and then probably by using the drug-bound form of the receptor...
  2. ncbi Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
    ....
  3. ncbi In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
    ..Equally, this raises hopes that a preventive vaccine could become effective at comparatively lower neutralizing antibody titers...
  4. ncbi HIV-host interactions: vital to the virus and key to its inhibition
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Opin Microbiol 7:555-9. 2004
    ..Nevertheless, current knowledge on the molecular interactions between HIV and host-cell factors has substantially broadened our understanding of the viral life cycle and opened new investigative areas for drug intervention...
  5. ncbi HIV-host interactions: vital to the virus and key to its inhibition
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Opin Microbiol 7:407-11. 2004
    ..Nevertheless, current knowledge on the molecular interactions between HIV and host-cell factors has substantially broadened our understanding of the viral life cycle and opened new investigative areas for drug intervention...
  6. ncbi Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008
    ..In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity...
  7. ncbi Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Blood 104:1784-92. 2004
    ..In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points...
  8. ncbi Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Virol 77:13146-55. 2003
    ....
  9. ncbi Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
    Michael Huber
    Division of Infectious Diseases, , , Switzerland
    PLoS Med 3:e441. 2006
    ....
  10. ncbi Association between specific HIV-1 Env traits and virologic control in vivo
    Beda Joos
    University Hospital Zurich, Department of Medicine, Switzerland
    Infect Genet Evol 10:365-72. 2010
    ..These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response...
  11. ncbi HIV rebounds from latently infected cells, rather than from continuing low-level replication
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:16725-30. 2008
    ..Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy...
  12. ncbi Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Antivir Ther 8:97-104. 2003
    ..In contrast, expression of HIV-UsRNAPBMC increased during STI and consequently provides a more sensitive, albeit not absolute cellular marker of ongoing HIV-1 replication...
  13. ncbi Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions
    Beda Joos
    University Hospital Zurich, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, , , Switzerland
    J Virol 79:9026-37. 2005
    ....
  14. ncbi Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
    ..Activities of these MAbs correlated significantly with each other, suggesting that common features of the viral envelope modulate their potencies...
  15. ncbi Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions
    Beda Joos
    Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, CH 8091, Switzerland
    J Infect Dis 196:313-20. 2007
    ....
  16. ncbi Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
    ..Further studies examining tissue concentrations to explain the differential in vivo activity of the anti-gp120 antibody compared with those of the two anti-gp41 antibodies are warranted...
  17. ncbi In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007
    ..This remarkable vulnerability of the virus to interference within the MPER calls for a further evaluation of the safety and efficacy of MPER-targeting therapeutic and vaccination strategies...
  18. ncbi Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol
    Peter Rusert
    Division of Infectious Diseases, University Hospital Zurich, Switzerland
    Virology 326:113-29. 2004
    ..Measuring viral infectivity may thereby function as an additional, useful marker in monitoring disease progression and evaluating efficacy of antivirals in vivo...
  19. ncbi Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts
    Marek Fischer
    Department of Medicine, University Hospital Zurich, Switzerland
    Antivir Ther 7:91-103. 2002
    ..As shown by limiting dilution analysis, HIV-1 infected cells with such a repressed viral transcription pattern were observed at high frequencies in PBMC from untreated patients...
  20. ncbi HIV RNA in plasma rebounds within days during structured treatment interruptions
    Marek Fischer
    Division of Infectious Diseases, , Switzerland
    AIDS 17:195-9. 2003
    ....
  21. ncbi HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia
    Huldrych F Gunthard
    Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland
    Clin Infect Dis 48:e117-20. 2009
    ..This evidence supports a mechanism other than cross-neutralizing antibodies for the mild course of HIV-1 infection in this woman...
  22. ncbi CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics
    Andreas Schweizer
    Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    PLoS Pathog 4:e1000109. 2008
    ....
  23. ncbi Divergent effects of cell environment on HIV entry inhibitor activity
    Peter Rusert
    Institute of Medical Virology, University of Zurich, University Hospital Zurich, Switzerland
    AIDS 23:1319-27. 2009
    ..In the present study, we investigate the influence the target cell context bears on HIV entry inhibition...
  24. ncbi MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
    Claudia R Ruprecht
    Institute of Medical Virology, University Hospital Zurich, Switzerland
    J Exp Med 208:439-54. 2011
    ....
  25. ncbi RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
    Branka Roscic-Mrkic
    Division of Infectious Diseases, Department of Medicine, University Hospital, Zurich, Switzerland
    Blood 102:1169-77. 2003
    ..Here we show that silencing of CD44 in HeLa-CD4 cells prevents the activation of p44/p42 MAPK and leads to a substantial reduction in HIV-1 infectivity enhancement by RANTES...
  26. ncbi The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C
    Tonie Cilliers
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
    J Virol 77:4449-56. 2003
    ..These observations are relevant to understanding the rapid spread of HIV-1 subtype C in the developing world and to the design of intervention and treatment strategies...
  27. ncbi Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
    Fotini Tsamis
    Microbiology and Immunology Department, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Virol 77:5201-8. 2003
    ..We propose that the binding of small molecules to the transmembrane domain of CCR5 may disrupt the conformation of its extracellular domain, thereby inhibiting ligand binding to CCR5...
  28. ncbi The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors
    Erika Billick
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 78:4134-44. 2004
    ..However, SCH-C is unable to exert this effect on CCR5 conformation when residue 198 is methionine. The region of CCR5 near residue 198 has, therefore, an important influence on the conformational state of this receptor...
  29. ncbi Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies
    Annette Oxenius
    Institute for Microbiology, Eidgenossische Technische Hochschule, Zurich, Switzerland
    J Infect Dis 190:713-21. 2004
    ..These findings demonstrate the temporal relationship between viral escape from CD8+ T cell activity, decrease in HIV-1-specific T cell frequencies, and loss of control of viral replication...
  30. ncbi Use of alternate coreceptors on primary cells by two HIV-1 isolates
    Tonie Cilliers
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    Virology 339:136-44. 2005
    ..Collectively, these data suggest that some HIV-1 isolates can use alternate coreceptors on primary cells, which may have implications for strategies that aim to block viral entry...
  31. ncbi Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity
    Theresa Li-Yun Chang
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, USA
    J Virol 76:2245-54. 2002
    ..Here we show that activation of both PTK and MAPK is involved in the enhancement of HIV-1 infectivity caused by RANTES in cells that lack GPCRs for RANTES but which express GAGs...
  32. ncbi A plea for justice for jailed medical workers
    Sunil K Ahuja
    Science 314:924-5. 2006